Immunotherapy for polyomaviruses: Opportunities and challenges

Immunotherapy

Volumn 4, Issue 6, 2012, Pages 617-628

  Dalianis, Tina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BK virus; human polyomavirus; immunotherapy; JC virus; Merkel cell polyomavirus; polyomavirus; trichodyplasia spinulosa polyomavirus; vaccine; virus like particle

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAPSID PROTEIN L1; CIDOFOVIR; CYCLOSPORIN A; DENDRITIC CELL VACCINE; NATALIZUMAB; PROTEIN VP1; PROTEIN VP2; TACROLIMUS; TUMOR ANTIGEN; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BK VIRUS; BK VIRUS INFECTION; BLOOD TRANSFUSION; GENE PRODUCT; GENE REPLICATION; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY DISEASE; MELANOMA; MERKEL CELL TUMOR; MULTIPLE SCLEROSIS; NONHUMAN; POLYOMA VIRUS; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VACCINE PRODUCTION; VIRION; VIRUS CAPSID; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS REPLICATION;

AGED; ANIMALS; CAPSID PROTEINS; CARCINOMA, MERKEL CELL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; SKIN NEOPLASMS; TUMOR VIRUS INFECTIONS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84863976772     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.51     Document Type: Review

References (100)

1. Gross L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc. Soc. Exp. Biol. Med. 83(2), 414-421 (1953
2. Stewart SE, Eddy BE, Gochenour AM, Borgese NG, Grubbs GE. The induction of neoplasms with a substance released from mouse tumors by tissue culture. Virology 3(2), 380-400 (1957
3. Berke Z, Dalianis T. Studies on polyomavirus persistence and polyomavirus-Induced tumor development in relation to the immune system. Adv. Cancer Res. 79, 249-276 (2000
4. Sweet BH, Hilleman MR. The vacuolating virus S.V.40. Proc. Soc. Exp. Biol. Med. 105, 420-427 (1960
5. Dang-Tan T, Mahmud SM, Puntoni R, Franco EL. Polio vaccines, simian virus 40, and human cancer: The epidemiologic evidence for a causal association. Oncogene 23(38), 6535-6540 (2004
6. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1(7712), 1253-1257 (1971
7. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-Like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1(7712), 1257-1260 (1971
8. Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: INNOCENT until proven guilty. Semin. Cancer Biol. 19(4), 252-260 (2009
9. Maginnis MS, Atwood WJ. JC virus: AN oncogenic virus in animals and humans? Semin. Cancer Biol. 19(4), 261-269 (2009
10. Dalianis T, Ljungman P. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res. 31(3), 939-944 (2004
11. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S136-S146 (2009
12. Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R. JC virus infection of the brain. AJNR Am. J. Neuroradiol. 31(9), 1564-1576 (2010
13. Allander T, Andreasson K, Gupta S et al. Identification of a third human polyomavirus. J. Virol. 81, 4130-4136 (2007
14. Gaynor AM, Nissen MD, Whiley DM et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 3(5), e64 (2007
15. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866), 1096-1100 (2008
16. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe 7(6), 509-515 (2010
17. Van Der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 6(7), e1001024 (2010
18. Scuda N, Hofmann J, Calvignac-Spencer S et al. A novel human polyomavirus closely related to the African green monkey-Derived lymphotropic polyomavirus. J. Virol. 85(9), 4586-4590 (2011
19. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 3, e1000363 (2009
20. Van Der Meijden E, Kazem S, Burgers MM et al. Seroprevalence of trichodysplasia spinulosa-Associated polyomavirus. Emerg. Infect. Dis. 17(8), 1355-1363 (2011
21. Trusch F, Klein M, Finsterbusch T, Kühn J, Hofmann J, Ehlers B. Seroprevalence of the human polyomavirus 9 (HPyV9) and cross-Reactivity to the African green monkey-Derived lymphotropic polyomavirus (LPV). J. Gen. Virol. 93(Pt 4), 698-705 (2012
22. Imperiale MJ, Major EO. Polyomaviridae. In: FIELDS Virology (5th Edition). Knipe DM, Howley PM, Griffin DE et al. (Eds). Lippincott Williams & Wilkins, PA, USA, 2263-2298 (2007
23. Johne R, Buck CB, Allander T et al. Taxonomical developments in the family Polyomaviridae. Arch. Virol. 156(9), 1627-1634 (2011
24. Brady JN, Consigli RA. Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein. J. Virol. 27, 436-442 (1978
25. Sasnauskas K, Bulavaite A, Hale A et al. Generation of recombinant virus-Like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 45(4-6), 308-317 (2002
26. Tegerstedt K, Andreasson K, Vlastos A, Hedlund KO, Dalianis T, Ramqvist T. Murine pneumotropic virus VP1 virus-Like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J. Gen. Virol. 84, 3443-3452 (2003
27. Viscidi RP, Rollison DE, Sondak VK et al. Age-Specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin. Vaccine Immunol. 18(10), 1737-1743 (2011
28. Chen T, Mattila PS, Jartti T, Ruuskanen O, Söderlund-Venermo M, Hedman K. Seroepidemiology of the newly found trichodysplasia spinulosa-Associated polyomavirus. J. Infect. Dis. 204(10), 1523-1156 (2011
29. Gu R, Zhang Z, DeCerbo JN, Carmichael GG. Gene regulation by sense-Antisense overlap of polyadenylations signals. RNA 15, 1154-1163 (2009
30. Freund R, Mandel G, Carmichael GG, Barncastle JP, Dawe CJ, Benjamin TL. Polyomavirus tumor induction in mice: INFLUENCES of viral coding and noncoding sequences on tumor profiles. J. Virol. 61(7), 2232-2239 (1987
31. Myhre MR, Olsen GH, Gosert R, Hirsch HH, Rinaldo CH. Clinical polyomavirus BK variants with agnogene deletion are non-Functional but rescued by trans-Complementation. Virology 398(1), 12-20 (2010
32. Gosert R, Kardas P, Major EO, Hirsch HH. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J. Virol. 84(20), 10448-10456 (2010
33. Neu U, Stehle T, Atwood WJ. The Polyomaviridae: Contributions of virus structure to our understanding of virus receptors and infectious entry. Virology 384(2), 389-399 (2009
34. Tegerstedt K, Franzén A, Andreasson K et al. Murine polyomavirus 'virus-Like' particles as vectors for gene and immune therapy and as vaccines. Anticancer Res. 2601-2608 (2005
35. Ramqvist T, Andreasson K, Dalianis T. Murine polyomavirus virus-Like particles (VLPs) as vectors for gene and immune therapy and vaccines. Future Virol. 2(3), 247-253 (2007
36. Ramqvist T, Andreasson K, Dalianis T. Vaccination, immune and gene therapy based on virus-Like particles against viral infections and cancer. Expert Opin Biol. Ther. 7(7), 997-1007 (2007
37. Garland SM, Smith JS. Human papillomavirus vaccines: Current status and future prospects. Drugs 70(9), 1079-1098 (2010
38. Chen XS, Casini G, Harrison SC, Garcea RL. Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1. J. Mol. Biol. 307(1), 173-182 (2001
39. Viscidi R, Clayman B. Serological cross reactivity between polyomavirus capsids. Adv. Exp. Med. Biol. 577, 73-84 (2006
40. Tegerstedt K, Lindencrona JA, Curcio C et al. A single vaccination with polyomavirus VP1/VP2Her2 virus-Like particles prevents outgrowth of HER-2/neu-Expressing tumors. Cancer Res. 65(13), 5953-5957 (2005
41. Heidari S, Krauzewicz N, Kalantari M, Vlastos A, Griffin BE, Dalianis T. Persistence and tissue distribution of DNA in normal and immunodeficient mice inoculated with polyomavirus VP1 pseudocapsid complexes or polyomavirus. J. Virol. 74, 11963-11965 (2000
42. Kimchi-Sarfaty C, Gottesman MM. SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr. Pharm. Biotechnol. 5(5), 451-458 (2004
43. Heidari S, Vlastos A, Ramqvist T et al. Immunization of T-Cell deficient mice against polyomavirus infection using viral pseudocapsids or temperature sensitive mutants. Vaccine 20, 1571-1578 (2002
44. Vlastos A, Andreasson K, Tegerstedt K et al. VP1 pseudocapsids, but not a glutathione-S-Transferase VP1 fusion protein, prevent polyomavirus infection in a T-Cell immune deficient experimental mouse model. J. Med. Virol. 70, 293-300 (2003
45. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-Antigen to papillomavirus-Like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108(3), 415-423 (2001
46. Maurer P, Jennings GT, Willers J et al. A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35(7), 2031-2040 (2005
47. Biel SS, Held TK, Landt O et al. Rapid quantification and differentiation of human polyomavirus DNA in undiluted urine from patients after bone marrow transplantation. J. Clin. Microbiol. 10, 3689-3695 (2000
48. Priftakis P, Bogdanovic G, Kokhaei P, Mellstedt H, Dalianis T. BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist. J. Clin. Virol. 26(1), 71-77 (2003
49. Bogdanovic G, Priftakis P, Giraud G et al. Association between a high BK virus load in urine samples of patients with graft-Versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J. Clin. Microbiol. 42(11), 5394-5396 (2004
50. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 98(6), 1971-1978 (2001
51. Bogdanovic G, Ljungman P, Wang F, Dalianis T. Presence of human polyomavirus DNA in the peripheral circulation of bone marrow transplant patients with and without hemorrhagic cystitis. Bone Marrow Transplant. 17(4), 573-576 (1996
52. Erard V, Kim HW, Corey L et al. BK DNA viral load in plasma: Evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 106(3), 1130-1132 (2005
53. Bogdanovic G, Priftakis P, Taemmeraes B et al. Primary BK virus (BKV) infection due to possible BKV transmission during bone marrow transplantation is not the major cause of hemorrhagic cystitis in transplanted children. Pediatr. Transplant. 2(4), 288-293 (1998
54. Priftakis P, Bogdanovic G, Kalantari M, Dalianis T. Overrepresentation of point mutations in the Sp1 site of the non-Coding control region of BK virus in bone marrow transplanted patients with haemorrhagic cystitis. J. Clin. Virol. 21(1), 1-7 (2001
55. El-Zimaity M, Saliba R, Chan K et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: Donor type matters. Blood 103(12), 4674-4680 (2004
56. Giraud G, Bogdanovic G, Priftakis P et al. The incidence of hemorrhagic cystitis and BK-Viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 91(3), 401-404 (2006
57. Giraud G, Priftakis P, Bogdanovic G et al. BK-Viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant. 41(8), 737-742 (2008
58. Atkinson K, Biggs JC, Golovsky D et al. Bladder irrigation does not prevent haemorrhagic cystitis in bone marrow transplant recipients. Bone Marrow Transplant. 7(5), 351-354 (1991
59. Cesaro S, Hirsch HH, Faraci M et al.; European Group for Blood and Marrow Transplantation. Cidofovir for BK virus-Associated hemorrhagic cystitis: A retrospective study. Clin. Infect. Dis. 49(2), 233-240 (2009
60. Leung AY, Mak R, Lie AK et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant. 29(6), 509-513 (2005
61. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-Virus and the impact of pre-Emptive immunosuppression reduction: 5-Year results. Am. J. Transplant. 10(2), 407-415 (2010
62. Schaub S, Hirsch HH, Dickenmann M et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus- Associated nephropathy. Am. J. Transplant. 10(12), 2615-2623 (2010
63. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-Induced demyelinating disease of the human brain. Clin. Microbiol. 5(1), 49-73 (1992
64. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J. Neurol. 258(11), 1920-1928 (2011
65. Kappos L, Bates D, Edan G et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol. 10(8), 745-758 (2011
66. Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: A clinicopathologic study with prognostic implications. J. Cutan. Pathol. 31(3), 217-223 (2004
67. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog. 5(9), e1000578 (2009
68. Kazem S, Van Der Meijden E, Kooijman S et al. Trichodysplasia spinulosa is characterized by active polyomavirus infection. J. Clin. Virol. 53(3), 225-230 (2012
69. Ramqvist T, Dalianis T. Murine polyomavirus tumour specific transplantation antigens and viral persistence in relation to the immune response, and tumour development. Semin. Cancer Biol. 9(4), 236-243 (2009
70. Berke Z, Dalianis T, Sandstedt K, Evengård B. Persistance of polyomavirus in SCID CB17 mice. In Vivo 8, 339-342 (1994
71. Berke Z, Wen T, Klein G, Dalianis T. Polyoma tumor development in CD4-/- and CD8-/- single knockout and CD4-/-8-/- double knockout mice. Int. J. Cancer 67(3), 405-408 (1996
72. Stolt A, Kjellin M, Sasnauskas K et al. Maternal human polyomavirus infection and risk of neuroblastoma in the child. Int. J. Cancer 113(3), 393-396 (2005
73. Priftakis P, Dalianis T, Carstensen J et al. Human polyomavirus DNA is not detected in Guthrie cards (dried blood spots) from children who have developed acute lymphoblastic leukemia. Med. Pediatr. Oncol. 40(4), 219-223 (2003
74. Gustafsson B, Honkaniemi E, Goh S et al. KI, WU and Merkel cell polyomavirus DNA was not detected in Guthrie cards of children, who later developed acute lymphoblastic leukemia (ALL). Pediat. Hematol. Oncol. (2012) (In Press
75. Sjogren HP, Hellstrom I, Klein G. Resistance of polyoma virus immunized mice against transplantation of extablished polyoma tumors. Exp. Cell Res. 23, 204-208 (1961
76. Ramqvist T, Pallas D, Deanda J et al. Immunization against the polyoma virus tumor specific transplantation antigen (TSTA) with polyoma T-Antigens. Int. J. Cancer 42, 123-128 (1988
77. Ramqvist T, Reinholdsson G, Carlquist M, Bergman T, Dalianis T. A single peptide derived from the sequence common to small and middle T-Antigen induces immunity against polyoma tumors. Virology 172, 359-362 (1989
78. Dalianis T. Studies on the polyoma virus tumor specific transplantation antigen (TSTA). Adv. Cancer Res. 55, 57-85 (1990
79. Reinholdsson Ljunggren G, Ramqvist T, Ährlund-Richter L, Dalianis T. Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle and large T-Antigens. Int. J. Cancer 50, 142-146 (1992
80. Reinholdsson Ljunggren G, Dalianis T. Modifications of an immunodominant peptide antigen induce different anti-polyoma tumor responses in two separate mouse strains. Int. J. Cancer 51, 968-972 (1992
81. Berke Z, Palmer S, Bergman T et al. A short peptide eluted from the H-2Kb molecule of a polyoma positive tumor corresponds to polyoma large T-Antigen amino acids 578-585 and induces polyoma specific immunity. J. Virol. 70 (5), 3093-3097 (1996
82. Ljunggren G, Ljunggren HG, Dalianis T. T-Cell subsets involved in immunity against polyoma virus induced tumours. Virology 198, 714-716 (1994
83. Lukacher AE, Ma Y, Carroll JP et al. Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen. J. Exp. Med. 181, 1683-1692 (1995
84. Wirth JJ, Amalfitano A, Gross R, Oldstone MB, Fluck MM. Organ- and age-Specific replication of polyomavirus in mice. J. Virol. 66, 3278-3286 (1992
85. Berke Z, Dalianis T. Persistance of polyomavirus in adult infected mice differs from that observed in new-Borns. J. Virol. 67, 4367-4371 (1993
86. Dubensky TW, Villarreal LP. The primary site of replication alters the eventual site of persistent infection by polyomavirus in mice. J. Virol. 50, 541-546 (1984
87. Swanson PA 2nd, Lukacher AE, Szomolanyi-Tsuda E. Immunity to polyomavirus infection: The polyomavirus-mouse model. Semin. Cancer Biol. 19(4), 244-251 (2009
88. Koralnick IJ, Du Pasquier RA, Kuroda MJ et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J. Immunol. 168, 499-504 (2002
89. Krymskaya L, Sharma MC, Martinez J et al. Cross-Reactivity of T-Lymphocytes recognizing a human cytotoxic T-Lymphocyte epitope within BK and JC virus VP1 polypeptides. J. Virol. 79, 11170-11178 (2005
90. Franzén AV, Tegerstedt K, Holländerova D et al. Murine polyomavirus VP1 virus-Like particles immunize against some polyomavirus induced tumors. In Vivo 19(2), 323-326 (2005
91. Ramqvist T, Dalianis T. Immunotherapeutic polyoma and human papilloma virus-Like particles (VLPs). Immunotherapy 2, 303-312 (2009
92. Tegerstedt K, Franzén A, Ramqvist T, Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-Like particles (VLPs) efficiently prevent outgrowth of a Her2/neu expressing tumor without inducing high anti-VLP serum titers. Cancer Immunol. Immunother. 56(9), 1335-1344 (2007
93. Andreasson K, Tegerstedt K, Eriksson et al. Murine pneumotropic virus chimeric Her2/neu virus-Like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumours. Int. J. Cancer 124(1), 150-156 (2009
94. Andreasson K, Eriksson M, Ramqvist T, Dalianis T. CD4+ and CD8+ T cells can act separately in tumour rejection after immunisation with murine pneumotropic virus chimeric Her2/neu virus-Like particles. PLoS ONE 5(7), e11580 (2010
95. Eriksson M, Andreasson K, Weidmann J et al. Murine polyomavirus virus-Like particles carrying full-Length human PSA can protect BALB/c mice from outgrowth of a PSA expressing tumour. PLoS ONE 6(8), e23828 (2011
96. Brinkman M, Walter J, Grein S et al. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-Coat protein carrying self or non-Self CD8 T cell epitopes against murine melanoma. Cancer Immunol. Immunother. 54(6), 611-622 (2005
97. Greenstone HL, Nieland JD, de Visser KE et al. Chimeric papillomavirus virus-Like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95, 1800-1805 (1998
98. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L. Chimeric virus-Like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch. Med. Res. 30(4), 269-274 (1999
99. Kaufman AM, Nieland JD, Jochmus I et al. Vaccination trial with HPV16 L1E7 chimeric virus-Like particles in women suffering from high grade intraepithelial neoplasia (CIN 2/3). Int. J. Cancer 121, 2794-2800 (2007
100. Nieto K, Gissmann L, Schädlich L. Human papillomavirus-Specific immune therapy: FAILURE and hope. Antivir. Ther. 15(7), 951-957 (2010)